Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to misleading statements regarding the safety of its clinical trial RP-A501, which led to significant investor losses [2][4][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Rocket Pharmaceuticals to contact them for legal options [1]. - A federal securities class action has been filed against Rocket Pharmaceuticals, with a deadline of August 11, 2025, for investors to seek the role of lead plaintiff [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Misleading Statements and Clinical Trial Issues - The complaint alleges that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [4]. - Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, which contributed to artificially inflated stock prices [4]. - On May 27, 2025, the FDA placed a clinical hold on the RP-A501 Phase 2 study after a patient suffered a Serious Adverse Event, including death, which was not disclosed to investors prior to the incident [5]. Group 3: Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in one trading day [6].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud between September 17, 2024, and May 26, 2025 [1]. - Defendants allegedly made positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) [2]. - Following the announcement of a clinical hold by the FDA due to a SAE, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until August 11, 2025, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

Core Points - A securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for alleged material misstatements and omissions affecting investors [1][3] - The lawsuit pertains to the period from September 17, 2024, to May 26, 2025, during which investors may seek compensation [2] - The lawsuit claims that Rocket Pharmaceuticals failed to disclose significant safety-related updates regarding its RP-A501 clinical trial, leading to a fatal adverse event and subsequent FDA clinical hold [3] Company Overview - Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, and specializes in gene therapies for rare and life-threatening diseases [2] - Following the public confirmation of the trial hold and patient death on May 28, 2025, Rocket Pharmaceuticals' stock price plummeted from $6.27 to $2.33 [3]

Core Viewpoint - The Rocket Pharmaceuticals class action lawsuit alleges violations of the Securities Exchange Act of 1934, focusing on misleading statements regarding the safety and clinical trial protocol of its gene therapy product RP-A501 [1][4]. Group 1: Lawsuit Details - The lawsuit is titled Ho v. Rocket Pharmaceuticals, Inc. and seeks to represent purchasers of Rocket Pharmaceuticals securities [1]. - A subsequent case, Yankov v. Rocket Pharmaceuticals, Inc., has also been filed [1]. - The lawsuit claims that Rocket Pharmaceuticals failed to disclose serious adverse events, including patient deaths, related to its clinical trials [4][5]. Group 2: Clinical Trial Allegations - Rocket Pharmaceuticals is accused of providing misleading information about its Phase 2 pivotal trial for RP-A501, particularly regarding the safety of the treatment and the introduction of a new immunomodulatory agent without proper disclosure [4]. - On May 27, 2025, the U.S. FDA placed a clinical hold on the RP-A501 study after a patient suffered a serious adverse event leading to death, which was not disclosed to investors at the time of the protocol amendment [5]. Group 3: Legal Process - Investors who purchased Rocket Pharmaceuticals securities during the class period can seek to be appointed as lead plaintiff in the lawsuit [6]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [6]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after a Serious Adverse Event was reported [3][4]. Summary by Sections Allegations - The complaint alleges that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety and clinical trial protocol, including the risk of Serious Adverse Events (SAEs) and participant deaths [3]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [3]. - Following the announcement of a clinical hold by the FDA due to a SAE, Rocket's stock price plummeted from $6.27 on May 23, 2025, to $2.33 on May 27, 2025, marking a decline of approximately 37% in one trading day [3]. Class Action Details - The class period for the lawsuit is defined as September 17, 2024, to May 26, 2025, and shareholders are encouraged to register for participation [3][4]. - The deadline for shareholders to seek lead plaintiff status is August 11, 2025, and there is no cost to participate in the case [4]. Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, aiming to ensure responsible business practices [5].

[PART I - FINANCIAL INFORMATION](index=6&type=section&id=PART%20I%20-%20FINANCIAL%20INFORMATION) [Financial Statements](index=6&type=section&id=Item%201.%20Financial%20Statements) Presents the unaudited consolidated financial statements for Q2 and H1 2025, reporting a net loss with no revenue generated Consolidated Balance Sheet Highlights | Financial Metric | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash, cash equivalents and investments | $271.5 million | $372.3 million | | Total Assets | $421.0 million | $527.7 million | | Total Liabilities | $66.8 million | $64.5 million | | Total Stockholders' Equity | $354.2 million | $463.2 million | Consolidated Statements of Operations Highlights | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | Revenue | $0 | $0 | | Research and development | $42.7 million | $46.3 million | | General and administrative | $25.0 million | $27.4 million | | Restructuring | $3.5 million | $0 | | **Net Loss** | **($68.9 million)** | **($69.6 million)** | | **Net Loss Per Share** | **($0.62)** | **($0.74)** | Consolidated Cash Flow Highlights | Cash Flow Activity | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($104.8 million) | ($110.7 million) | | Net cash (used in) provided by investing activities | ($26.3 million) | $90.7 million | | Net cash provided by financing activities | $0.2 million | $2.7 million | [Notes to Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) Provides details on accounting policies, liquidity risks, a corporate reorganization, and a clinical hold on the RP-A501 trial - Rocket is a late-stage biotechnology company developing gene therapies for rare cardiovascular and hematology disorders[32](index=32&type=chunk)[33](index=33&type=chunk)[34](index=34&type=chunk) - As of June 30, 2025, the company had an accumulated deficit of **$1.35 billion**, with cash and investments of **$271.5 million** expected to fund operations into Q2 2027[37](index=37&type=chunk) - In July 2025, the company initiated a strategic reorganization involving a **30% workforce reduction** and a restructuring charge of approximately **$3.5 million**[40](index=40&type=chunk)[110](index=110&type=chunk)[111](index=111&type=chunk) - In May 2025, the FDA placed a clinical hold on the Phase 2 trial for RP-A501 for Danon disease following a Serious Adverse Event (SAE)[39](index=39&type=chunk)[54](index=54&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=25&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Details management's perspective on financial condition, operational results, a strategic reorganization, and key clinical updates [Overview and Strategy](index=25&type=section&id=Overview%20and%20Strategy) Outlines the strategic shift to prioritize the AAV cardiovascular platform, reduce operating expenses, and seek external partnerships - In July 2025, the company announced a strategic corporate reorganization to focus resources on its AAV cardiovascular platform and respond to the CRL for KRESLADI™[119](index=119&type=chunk) - The restructuring included a **30% workforce reduction** and is expected to reduce 12-month operating expenses by nearly **25%**[119](index=119&type=chunk) - The company is actively exploring external partnership options for its Fanconi Anemia (RP-L102) and Pyruvate Kinase Deficiency (RP-L301) programs[173](index=173&type=chunk)[179](index=179&type=chunk) [Pipeline Overview](index=27&type=section&id=Pipeline%20Overview) Reviews the company's pipeline, highlighting the clinical hold on RP-A501 and the Complete Response Letter for KRESLADI™ - The FDA placed the Phase 2 pivotal trial for RP-A501 (Danon disease) on clinical hold on May 23, 2025, after a patient experienced a Serious Adverse Event (SAE)[151](index=151&type=chunk)[152](index=152&type=chunk) - In June 2024, the FDA issued a Complete Response Letter (CRL) for the KRESLADI™ (RP-L201) BLA for LAD-I, requesting additional CMC information[166](index=166&type=chunk) - For the Fanconi Anemia program (RP-L102), an MAA was accepted by the EMA, but the company is now seeking external partners for regulatory filings[173](index=173&type=chunk) [Results of Operations](index=38&type=section&id=Results%20of%20Operations) Compares financial results for the six months ended June 30, 2025 and 2024, noting changes in R&D and G&A expenses Comparison of Operations | Metric | Six Months Ended June 30, 2025 ($M) | Six Months Ended June 30, 2024 ($M) | Change ($M) | | :--- | :--- | :--- | :--- | | R&D Expenses | 78.6 | 91.6 | (13.0) | | G&A Expenses | 53.5 | 49.5 | 4.0 | | Restructuring | 3.5 | 0.0 | 3.5 | | **Net Loss** | **(130.3)** | **(131.7)** | **1.4** | - The decrease in R&D expenses for the six-month period was primarily driven by lower manufacturing costs (**$4.8M**), professional fees (**$3.6M**), and a **$2.7M** CIRM grant[207](index=207&type=chunk) - The increase in G&A expenses for the six-month period was primarily driven by a **$4.3 million increase** in legal expenses[208](index=208&type=chunk) [Liquidity and Capital Resources](index=39&type=section&id=Liquidity%20and%20Capital%20Resources) Assesses the company's financial position, including its cash balance, accumulated deficit, and projected cash runway into Q2 2027 - As of June 30, 2025, the company had **$271.5 million** in cash, cash equivalents, and investments and an accumulated deficit of **$1.35 billion**[213](index=213&type=chunk) - The company believes its current financial resources are sufficient to fund operating expenses and capital expenditure requirements into the **second quarter of 2027**[213](index=213&type=chunk) - Net cash used in operating activities was **$104.8 million** for the six months ended June 30, 2025, compared to $110.7 million for the same period in 2024[215](index=215&type=chunk)[216](index=216&type=chunk)[217](index=217&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=41&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) Discusses the company's exposure to interest rate risk on its investment portfolio and the potential impact of rate changes - The company's primary market risk is interest rate sensitivity on its **$271.5 million** portfolio of cash, cash equivalents, and investments as of June 30, 2025[223](index=223&type=chunk) - A hypothetical uniform **100-basis-point increase** in interest rates would result in a decline of **$0.7 million** in the net fair value of the company's investments[224](index=224&type=chunk) [Controls and Procedures](index=42&type=section&id=Item%204.%20Controls%20and%20Procedures) Confirms the effectiveness of the company's disclosure controls and procedures as of the end of the reporting period - Management concluded that the company's disclosure controls and procedures were **effective** as of June 30, 2025[226](index=226&type=chunk) - There were **no material changes** to the company's internal control over financial reporting during the quarter[229](index=229&type=chunk) [PART II - OTHER INFORMATION](index=43&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) [Legal Proceedings](index=43&type=section&id=Item%201.%20Legal%20Proceedings) Details the settlement of litigation with Lexeo Therapeutics and the filing of two new securities class action lawsuits - In June 2025, the company settled litigation with Lexeo Therapeutics, Inc, with the financial impact being **not material**[230](index=230&type=chunk)[231](index=231&type=chunk) - Two securities class action lawsuits were filed against the company in June and July 2025 related to public statements about the Phase 2 clinical trial for RP-A501[232](index=232&type=chunk) [Risk Factors](index=43&type=section&id=Item%201A.%20Risk%20Factors) Highlights new risks related to securities litigation costs and the potential challenges of the recent strategic restructuring - A new risk factor is the potential for substantial costs and diversion of management resources due to recently filed securities class action lawsuits[235](index=235&type=chunk)[236](index=236&type=chunk) - The company's strategic restructuring may not achieve anticipated savings and could lead to unforeseen difficulties, unexpected costs, or attrition[238](index=238&type=chunk)[239](index=239&type=chunk) [Other Information (Items 2-6)](index=44&type=section&id=Items%202-6.%20Other%20Information) Covers standard disclosures including unregistered equity sales, senior securities defaults, and Rule 10b5-1 trading plans - There were no unregistered sales of equity securities or defaults upon senior securities during the period[240](index=240&type=chunk)[241](index=241&type=chunk) - No directors or officers adopted or terminated a Rule 10b5-1 trading arrangement during the three months ended June 30, 2025[243](index=243&type=chunk)

[Report Overview](index=1&type=section&id=Report%20Overview) [Strategic and Financial Highlights](index=1&type=section&id=Strategic%20and%20Financial%20Highlights) Rocket Pharmaceuticals announced a strategic pivot to prioritize its AAV cardiovascular gene therapy platform, alongside a significant organizational restructuring aimed at reducing costs. The company reported a cash position of $271.5 million, providing an operational runway into the second quarter of 2027, and appointed Chris Stevens as the new Chief Operating Officer - Strategic focus has been refined to prioritize the development of the AAV cardiovascular gene therapy platform, specifically RP-A501 (Danon disease), RP-A601 (PKP2-ACM), and RP-A701 (BAG3-DCM)[1](index=1&type=chunk) - An organizational restructuring is underway, expected to reduce headcount by approximately **30%** and lower the 12-month cash burn by nearly **25%**[1](index=1&type=chunk)[8](index=8&type=chunk) - The company reported cash, cash equivalents, and investments of approximately **$271.5 million**, which is expected to fund operations into the second quarter of **2027**[1](index=1&type=chunk)[9](index=9&type=chunk) - Chris Stevens has been appointed as the new Chief Operating Officer[1](index=1&type=chunk)[6](index=6&type=chunk) [CEO's Statement](index=1&type=section&id=CEO%27s%20Statement) The CEO, Gaurav Shah, M.D., highlighted the second quarter of 2025 as an inflection point where the company sharpened its focus on its high-value AAV cardiovascular platform. He noted that this strategic shift, which includes pausing investments in the Fanconi Anemia (FA) and Pyruvate Kinase Deficiency (PKD) programs, strengthens the company's financial foundation and positions it as a leader in gene therapies for inherited cardiomyopathies - The company is fortifying its path to sustained value creation by focusing on programs with the highest value, conserving cash, and driving an efficient organization[3](index=3&type=chunk) - Rocket is pausing additional investments in its Fanconi Anemia (FA; RP-L102) and Pyruvate Kinase Deficiency (PKD; RP-L301) programs and is exploring strategic alternatives to advance them externally[3](index=3&type=chunk)[8](index=8&type=chunk) - The CEO expressed confidence that the recent reorganization ensures the company is appropriately resourced to execute on near-term milestones with nearly **two years of capital**[3](index=3&type=chunk) [Recent Progress and Updates](index=2&type=section&id=Recent%20Progress%20and%20Updates) [Pipeline Updates](index=2&type=section&id=Pipeline%20Updates) The company provided key updates on its clinical pipeline. The Phase 2 study for RP-A501 (Danon disease) was placed on clinical hold by the FDA following a serious adverse event. In contrast, RP-A601 (PKP2-ACM) and RP-A701 (BAG3-DCM) received positive regulatory designations (RMAT and Fast Track, respectively), advancing them toward pivotal trials and clinical entry. The FDA review for KRESLADI™ (LAD-I) is ongoing, with a BLA submission expected by year-end 2025 [RP-A501 (Danon Disease)](index=2&type=section&id=RP-A501%20(Danon%20Disease)) The Phase 2 pivotal study for RP-A501 was placed on clinical hold by the FDA following a patient death, prompting a root cause analysis - The Phase 2 pivotal study for RP-A501 is on clinical hold by the FDA as of May 23, **2025**, following a Serious Adverse Event (SAE) that unfortunately led to a patient's death[4](index=4&type=chunk) - A root cause analysis is underway, focusing on the recent addition of a C3 inhibitor to the pre-treatment regimen[4](index=4&type=chunk) [RP-A601 (PKP2-ACM)](index=2&type=section&id=RP-A601%20(PKP2-ACM)) RP-A601 received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, with the company engaging the FDA on a potential pivotal trial design following encouraging Phase 1 data - Received FDA Regenerative Medicine Advanced Therapy (RMAT) designation in July **2025**[1](index=1&type=chunk)[4](index=4&type=chunk) - Following encouraging initial Phase 1 data presented at ASGCT, Rocket is actively engaging with the FDA on a potential pivotal trial design[1](index=1&type=chunk)[4](index=4&type=chunk) [RP-A701 (BAG3-DCM)](index=2&type=section&id=RP-A701%20(BAG3-DCM)) The IND application for RP-A701 was cleared by the FDA, and the program received Fast Track designation, with Phase 1 trial start-up activities now underway - The Investigational New Drug (IND) application was cleared by the FDA in June **2025**[4](index=4&type=chunk) - RP-A701 was granted FDA Fast Track designation, and Phase 1 trial start-up activities are now underway[1](index=1&type=chunk)[4](index=4&type=chunk) [KRESLADI™ (LAD-I)](index=2&type=section&id=KRESLADI%E2%84%A2%20(LAD-I)) The FDA is reviewing additional CMC information for KRESLADI™, with the company expecting to submit the complete BLA to resolve the Complete Response Letter by year-end 2025 - The FDA is conducting a review of limited additional Chemistry Manufacturing and Controls (CMC) information for KRESLADI™[4](index=4&type=chunk) - The company anticipates submitting the complete Biologics License Application (BLA) to resolve the Complete Response Letter before the end of **2025**[4](index=4&type=chunk) [Corporate and Operational Updates](index=3&type=section&id=Corporate%20and%20Operational%20Updates) Rocket has executed a strategic corporate restructuring, reducing its workforce by approximately 30% to align with its prioritized focus on the AAV cardiovascular platform. This move is expected to cut operating expenses by nearly 25% over the next year. As part of this realignment, the company has paused further investment in its Fanconi Anemia and Pyruvate Kinase Deficiency programs. Additionally, Chris Stevens was appointed as the new Chief Operating Officer - Implemented a workforce reduction of approximately **30%** across all functions to align with the pipeline prioritization plan[8](index=8&type=chunk) - The restructuring and other cost-saving measures are expected to reduce operating expenses by nearly **25%** over the next **12 months**[8](index=8&type=chunk) - As part of the realignment, the company is pausing additional investments in its Fanconi Anemia (FA) and Pyruvate Kinase Deficiency (PKD) programs[8](index=8&type=chunk) - Appointed Chris Stevens, a seasoned executive with **25 years of experience** from Spark Therapeutics, as Chief Operating Officer[6](index=6&type=chunk) [Second Quarter 2025 Financial Results](index=3&type=section&id=Second%20Quarter%202025%20Financial%20Results) [Key Financial Metrics](index=3&type=section&id=Key%20Financial%20Metrics) For the second quarter of 2025, Rocket Pharmaceuticals reported a net loss of $68.9 million, or $0.62 per share, a slight improvement from the $69.6 million net loss in Q2 2024. The company reduced both R&D and G&A expenses year-over-year and ended the quarter with a solid cash position of $271.5 million Key Financial Metrics (in millions) | Financial Metric | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | Cash, Cash Equivalents & Investments | $271.5M | N/A | - | | R&D Expenses | $42.7M | $46.3M | ($3.6M) | | G&A Expenses | $25.0M | $27.4M | ($2.4M) | | Net Loss | ($68.9M) | ($69.6M) | $0.7M | | Net Loss Per Share | ($0.62) | ($0.74) | $0.12 | - The decrease in R&D expenses was primarily driven by lower costs for manufacturing, direct materials, and professional fees[9](index=9&type=chunk) - The decrease in G&A expenses was mainly due to reduced commercial preparation and compensation-related expenses[15](index=15&type=chunk) [Restructuring Expenses and Financial Guidance](index=4&type=section&id=Restructuring%20Expenses%20and%20Financial%20Guidance) The company incurred approximately $3.5 million in restructuring and related charges during the first half of 2025. Management expects its current cash, cash equivalents, and investments of $271.5 million will be sufficient to fund operations into the second quarter of 2027 - Approximately **$3.5 million** in restructuring and related charges were incurred in the first half of **2025**[10](index=10&type=chunk) - The company's cash runway is expected to extend into the second quarter of **2027**, excluding any potential proceeds from a Priority Review Voucher[9](index=9&type=chunk) [Consolidated Financial Statements](index=6&type=section&id=Consolidated%20Financial%20Statements) The consolidated statements of operations detail the company's financial performance for the three and six months ending June 30, 2025, showing a reduction in total operating expenses compared to the prior year. The balance sheet reflects total assets of $421.0 million and total stockholders' equity of $354.2 million as of June 30, 2025 Consolidated Statements of Operations (in thousands) | Statement of Operations | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | Research and development | $42,658 | $46,345 | | General and administrative | $25,020 | $27,367 | | Restructuring | $3,471 | $0 | | **Total operating expenses** | **$71,149** | **$73,712** | | **Loss from operations** | **($71,149)** | **($73,712)** | | **Net loss** | **($68,919)** | **($69,646)** | | **Net loss per share** | **($0.62)** | **($0.74)** | Consolidated Balance Sheets (in thousands) | Balance Sheet | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash, cash equivalents, and investments | $271,494 | $372,336 | | Total assets | $420,979 | $527,700 | | Total liabilities | $66,768 | $64,466 | | Total stockholders' equity | $354,211 | $463,234 | [Corporate Information](index=4&type=section&id=Corporate%20Information) [About Rocket Pharmaceuticals, Inc.](index=4&type=section&id=About%20Rocket%20Pharmaceuticals%2C%20Inc.) Rocket Pharmaceuticals is a late-stage biotechnology company developing a pipeline of genetic therapies for rare and complex disorders. The company utilizes a multi-platform approach, with an adeno-associated viral (AAV) vector-based portfolio for cardiovascular diseases and a lentiviral (LV) vector-based portfolio for hematology disorders - The company's AAV cardiovascular portfolio includes late-stage programs for Danon Disease and early-stage programs for PKP2-arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy[12](index=12&type=chunk) - The LV hematology portfolio consists of late-stage programs for Leukocyte Adhesion Deficiency-I (LAD-I), Fanconi Anemia (FA), and Pyruvate Kinase Deficiency (PKD)[13](index=13&type=chunk) [Forward-Looking Statements](index=5&type=section&id=Forward-Looking%20Statements) This section serves as a cautionary notice to investors, stating that the press release contains forward-looking statements that are subject to significant risks and uncertainties. These statements, which are not guarantees of future performance, pertain to the company's plans, clinical trial timings, regulatory outcomes, and financial projections. Readers are advised not to place undue reliance on them - The press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of **1995**[16](index=16&type=chunk) - These statements involve risks and uncertainties that could cause actual results to differ materially from expectations, including the ability to realize benefits from restructuring, trial outcomes, and regulatory decisions[16](index=16&type=chunk)

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 11, 2025 [1] Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities between September 17, 2024, and May 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 11, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm for more information [6] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4] Group 3: Case Allegations - The lawsuit alleges that Rocket Pharmaceuticals made false and misleading statements regarding the effectiveness and safety of RP-A501, which was overstated [5] - It is claimed that the introduction of a novel immunomodulatory agent to increase RP-A501's effectiveness raised the risk of Serious Adverse Events (SAEs) for patients [5] - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading public statements made by the defendants [5]

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between September 17, 2024, and May 26, 2025 [1]. - Defendants allegedly provided misleading statements about the safety of RP-A501 while concealing serious adverse events, including participant deaths during the clinical trial [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 to $2.33 per share, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until August 11, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the United States [4].

Core Points - A securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for alleged material misstatements and omissions affecting investors [1][3] - The lawsuit pertains to the period from September 17, 2024, to May 26, 2025, during which investors may seek compensation [2] - The lawsuit claims that Rocket Pharmaceuticals failed to disclose significant safety-related updates regarding its RP-A501 clinical trial, leading to a fatal adverse event and subsequent FDA clinical hold [3] Company Information - Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, and specializes in gene therapies for rare and life-threatening diseases [2] - Following the public confirmation of the trial hold and patient death on May 28, 2025, Rocket Pharmaceuticals' stock price plummeted from $6.27 to $2.33 [3]